Slovénie - slovène - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

novartis pharma gmbh - deksametazon; tobramicin - mazilo za oko - deksametazon 1 mg / 1 g  tobramicin3 mg / 1 g; tobramicin 3 mg / 1 g - deksametazon in protimikrobne učinkovine

Slovénie - slovène - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

novartis pharma gmbh - deksametazon; tobramicin - kapljice za oko, suspenzija - deksametazon 1 mg / 1 ml  tobramicin3 mg / 1 ml; tobramicin 3 mg / 1 ml - deksametazon in protimikrobne učinkovine

Slovénie - slovène - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

prašek in vehikel za suspenzijo za injiciranje (s podaljšanim sproščanjem) - triptorelin

Slovénie - slovène - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alkaloid - int d.o.o. - askorbinska kislina (vitamin c), paracetamol, psevdoefedrinijev klorid, dekstrometorfanijev bromid - filmsko obložena tableta - askorbinska kislina (vitamin c) 60 mg / 1 tableta; paracetamol 500 mg / 1 tableta; psevdoefedrinijev klorid 30 mg / 1 tableta; dekstrometorfanijev bromid 15 mg / 1 tableta - paracetamol, kombinacije s psiholeptiki

Slovénie - slovène - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

glaxosmithkline consumer healthcare (uk) trading limited - flutikazonpropionat - pršilo za nos, suspenzija - flutikazonpropionat 50 µg / 1 vpih - flutikazon

Slovénie - slovène - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

farmedica d.o.o. ljubljana - gosti ekstrakt plodu palmeta - kapsula, mehka - gosti ekstrakt plodu palmeta 320 mg / 1 tableta - plod palmeta

Union européenne - slovène - EMA (European Medicines Agency)

teva b.v. - clopidogrel (as hydrogen sulfate) - myocardial infarction; acute coronary syndrome; peripheral vascular diseases; stroke - antitrombotična sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. za odrasle bolnike, ki trpijo za akutni koronarni sindrom:non-st segmentu višinskih akutni koronarni sindrom (nestabilna angina pektoris ali ne-q-val, miokardni infarkt), vključno z bolniki, ki opravljajo stent umestitev po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilne kisline (asa). st segmentu višinskih akutni miokardni infarkt, v kombinaciji s asa v medicinsko zdravljenih bolnikih, ki izpolnjujejo pogoje za thrombolytic terapija. preprečevanje atherothrombotic in thromboembolic dogodkov v atrijska fibrillationin odraslih bolnikov z atrijsko fibrilacijo, ki imajo vsaj en dejavnik tveganja za žilne dogodke, niso primerni za zdravljenje z antagonisti vitamina k (vka) in ki imajo nizko tveganje krvavitve, clopidogrel je indiciran v kombinaciji s asa za preprečevanje atherothrombotic in thromboembolic dogodkov, vključno z možgansko kap.

Union européenne - slovène - EMA (European Medicines Agency)

mylan pharmaceuticals limited - darunavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):za zdravljenje okužbe z virusom hiv-1 okužba v protiretrovirusno zdravljenje (art)-izkušeni odraslih bolnikih, vključno s tistimi, ki so bili zelo pre-obravnava. za zdravljenje okužbe z virusom hiv-1 okužba pri pediatričnih bolnikih od starosti 3 let in najmanj 15 kg telesne teže. pri odločanju za uvedbo zdravljenja z darunavir co-daje z nizkim odmerkom ritonavir, previdni, upoštevati je treba zdravljenje zgodovino posameznih bolnikov in vzorcev mutacije, povezane z različnimi agenti. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 in 5. darunavir co-daje z nizkim odmerkom ritonavir je navedeno v kombinaciji z drugimi protiretrovirusnimi zdravili za zdravljenje bolnikov z virusom humane imunske pomanjkljivosti (hiv-1) okužbe.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. pri odločanju za uvedbo zdravljenja z darunavir v takih art-izkušeni bolniki, genotipa testiranje mora vodnik za uporabo darunavir (glej točki 4. 2, 4. 3, 4. 4 in 5.

Union européenne - slovène - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 in 5.

Union européenne - slovène - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degareliks - prostatične neoplazme - endokrini terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.